He obtained a Ph.D. in health and biology from the University of Montpellier, France, focusing on gene therapy in joint diseases, where a constellation of gene therapy strategies were used included RNA interference, viral- and liposome-based vectors. The successful outcome of these approaches resulted in multiple high impact publications, conveying the opportunity for a postdoctoral position at the MIT, Koch Institute, Cambridge, Massachusetts. At MIT, he focused his effort on establishing a humanized mouse model; a mouse with a human blood system. This was followed by a position at the MIT-Singapore alliance for research and technology (SMART), in Singapore, where he worked on hematopoietic and fetal stem cells. Following this enriching experience, he established his own research laboratory of nanoRegenerative medicine, in Santiago de Chile, where he currently directs a young team of highly motivated researchers. The laboratory is located at the Universidad de Los Andes and affiliated to a biotechnology venture, Cells for Cells, where he currently hold a dual position as an A/Professor and Chief Scientific Officer (CSO) at Cells for Cells and Regenero (co-founder), the Chilean consortium for Regenerative medicine.

With a keen interest in bridging the bench work to the bedside, his team is carrying out research with the objective of developing treatments and therapeutics against diseases of public health and economic importance that are impacting the daily life of people living in Chile. This vanguard expertise was capitalized in several clinical application in diseases with unmet medical needs such as heart failure, Osteoarthritis, lupus and pulpitis.